Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07203378 · ClinicalTrials.gov registry record · Phase 2

Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu

A Phase 2 study of Metastatic Breast Cancer, sponsored by University of Utah.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT07203378 is a Phase 2 study of Metastatic Breast Cancer that is actively recruiting participants, run by University of Utah. The registered enrollment target is 80 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07203378, a Phase 2 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by University of Utah.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.

Conditions Studied

Interventions

  • OTHER Whole-body resistance training and aerobic exercise

Study Locations (1)

Utah

  • Huntsman Cancer Institute at University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-11-04
Est. Completion 2028-11
Phase Phase 2

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT07203378

The ClinicalTrials.gov registry entry for NCT07203378 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (61% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Whole-body resistance training and aerobic exercise is the first listed.

NCT07203378 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT07203378 about?

NCT07203378 is a clinical study titled "Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu". The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.

What is the current status of trial NCT07203378?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-11-04. Estimated completion is 2028-11.

What conditions does trial NCT07203378 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT07203378?

The interventions under investigation include: Whole-body resistance training and aerobic exercise (OTHER).

Who is sponsoring clinical trial NCT07203378?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07203378 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.